Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Ogan

Showing results (161-170 of 167) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 167 results.
Urology Practice|June 15, 2026
Contemporary Validation of the Renal Cell Carcinoma Inflammatory Score (RISK) for Preoperative Prognostication in Non-Metastatic Renal Cell CarcinomaAdam Braunschweig, Gabriel Ekene Agu, Reza Lahiji, et al.
The Journal of Urology|April 25, 2008
Prospective randomized trial comparing shock wave lithotripsy and ureteroscopy for lower pole caliceal calculi 1 cm or lessMargaret S Pearle, James E Lingeman, Raymond Leveillee, et al.
The Journal of Urology|May 10, 2005
Prospective, randomized trial comparing shock wave lithotripsy and ureteroscopy for lower pole caliceal calculi 1 cm or lessMargaret S Pearle, James E Lingeman, Raymond Leveillee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2017
Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized StudyNeal D Shore, Stephen A Boorjian, Daniel J Canter, et al.
Research Square|August 16, 2024
Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trialMehmet A Bilen, BaoHan T Vo, Yuan Liu, et al.
Nature Cancer|February 27, 2025
Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trialMehmet A Bilen, BaoHan T Vo, Yuan Liu, et al.
The Lancet. Oncology|June 28, 2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 studyMohamad E Allaf, Se-Eun Kim, Viraj Master, et al.
Pageof 17

Showing results (161-170 of 167) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 167 results.
Urology Practice|June 15, 2026
Contemporary Validation of the Renal Cell Carcinoma Inflammatory Score (RISK) for Preoperative Prognostication in Non-Metastatic Renal Cell CarcinomaAdam Braunschweig, Gabriel Ekene Agu, Reza Lahiji, et al.
The Journal of Urology|April 25, 2008
Prospective randomized trial comparing shock wave lithotripsy and ureteroscopy for lower pole caliceal calculi 1 cm or lessMargaret S Pearle, James E Lingeman, Raymond Leveillee, et al.
The Journal of Urology|May 10, 2005
Prospective, randomized trial comparing shock wave lithotripsy and ureteroscopy for lower pole caliceal calculi 1 cm or lessMargaret S Pearle, James E Lingeman, Raymond Leveillee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2017
Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized StudyNeal D Shore, Stephen A Boorjian, Daniel J Canter, et al.
Research Square|August 16, 2024
Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trialMehmet A Bilen, BaoHan T Vo, Yuan Liu, et al.
Nature Cancer|February 27, 2025
Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trialMehmet A Bilen, BaoHan T Vo, Yuan Liu, et al.
The Lancet. Oncology|June 28, 2024
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 studyMohamad E Allaf, Se-Eun Kim, Viraj Master, et al.
Pageof 17